Related references
Note: Only part of the references are listed.Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Ser vice Population
Sanjay Sethi et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2022)
Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey
David Mannino et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2022)
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Daiana Stolz et al.
LANCET (2022)
Prospects for COPD treatment
Maria Gabriella Matera et al.
CURRENT OPINION IN PHARMACOLOGY (2021)
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
Gary T. Ferguson et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2021)
Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD)
Biju Thomas et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2021)
Pharmacologic Management of Chronic Obstructive Pulmonary Disease An Official American Thoracic Society Clinical Practice Guideline
Linda Nici et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4
Mark J. Turner et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis
Henrik Watz et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020)
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
Dave Singh et al.
RESPIRATORY RESEARCH (2020)
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Dave Singh et al.
RESPIRATORY RESEARCH (2020)
Phosphodiesterases as therapeutic targets for respiratory diseases
Haoxiao Zuo et al.
PHARMACOLOGY & THERAPEUTICS (2019)
The future of bronchodilation: looking for new classes of bronchodilators
Mario Cazzola et al.
EUROPEAN RESPIRATORY REVIEW (2019)
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Symptomatic burden of COPD for patients receiving dual or triple therapy
Stephanie Chen et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
Donald P. Tashkin et al.
RESPIRATORY RESEARCH (2018)
Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice
S. Vamsee Raju et al.
RESPIRATORY RESEARCH (2017)
The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia
Mark J. Turner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2016)
Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility
R. Venkatasamy et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways
Luigino Calzetta et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials
Nancy K. Leidy et al.
RESPIRATORY RESEARCH (2014)
Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease
Andrea Gershon et al.
JAMA INTERNAL MEDICINE (2013)
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
Lui G. Franciosi et al.
LANCET RESPIRATORY MEDICINE (2013)
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone
Luigino Calzetta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Inhaled Anticholinergic Drug Therapy and the Risk of Acute Urinary Retention in Chronic Obstructive Pulmonary Disease
Anne Stephenson et al.
ARCHIVES OF INTERNAL MEDICINE (2011)
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages
J. Milara et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2011)
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease.
John R. Hurst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
Katharine H. Banner et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
Leonardo M. Fabbri et al.
LANCET (2009)
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Peter M. A. Calverley et al.
LANCET (2009)
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
Victoria Boswell-Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways
DT Schmidt et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
